Summary
2.19 -0.07(-2.89%)07/01/2024
Xeris Pharmaceuticals Inc (XERS)
Xeris Pharmaceuticals Inc (XERS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.89 | 3.31 | -10.82 | 2.11 | -3.74 | -14.31 | -81.15 | -89.19 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.19 | |
| Open | 2.24 | |
| High | 2.26 | |
| Low | 2.16 | |
| Volume | 718,470 | |
| Change | -0.07 | |
| Change % | -2.89 | |
| Avg Volume (20 Days) | 887,124 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 1.46 - 3.26 | |
| Price vs 52 Week High | -32.98% | |
| Price vs 52 Week Low | 49.66% | |
| Range | -2.46 | |
| Gap Up/Down | -0.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 334 | |
| EBIDTA | -94,216,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 6.25 | |
| Book Value | 0.6690 | |
| Earnings Per Share | -0.7520 | |
| EPS Estimate Current Quarter | -0.3600 | |
| EPS Estimate Next Quarter | -0.3300 | |
| EPS Estimate Current Year | -1.2600 | |
| EPS Estimate Next Year | -0.4900 | |
| Diluted EPS (TTM) | -0.7520 | |
| Revenues | ||
| Profit Marging | -2.6545 | |
| Operating Marging (TTM) | -2.3923 | |
| Return on asset (TTM) | -0.3503 | |
| Return on equity (TTM) | -15.7966 | |
| Revenue TTM | 35,333,000 | |
| Revenue per share TTM | 0.2830 | |
| Quarterly Revenue Growth (YOY) | 0.1710 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 11,207,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 13.4073 | |
| Revenue Enterprise Value | 7.6958 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 124,709,000 | |
| Shares Float | 124,035,507 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.58 | |
| Institutions (%) | 17.09 | |
06/03 07:00 EST - businesswire.com
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing's syndrome at ENDO 2024 in Boston, June 1-4, 2024. “The results of this analysis suggest that pati.
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing's syndrome at ENDO 2024 in Boston, June 1-4, 2024. “The results of this analysis suggest that pati.
05/30 07:30 EST - businesswire.com
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company's XeriSol™ formulation technology to enable a novel once-weekly SC injec.
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company's XeriSol™ formulation technology to enable a novel once-weekly SC injec.
05/30 07:00 EST - businesswire.com
Xeris to Participate in the Jefferies Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time. A live webcast of the event will be available on the 'Events & Presentations.
Xeris to Participate in the Jefferies Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time. A live webcast of the event will be available on the 'Events & Presentations.
05/09 10:14 EST - proactiveinvestors.com
Xeris Biopharma sees 1Q revenue jump on strength of product sales
Xeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter, with total product revenue surging 25% compared to the previous year's quarter. Paul Edick, CEO of Xeris, cited significant momentum in Recorlev sales, the steadfastness of Keveyis in the market, and the expanding market share of Gvoke as key drivers of the firm's performance over the quarter.
Xeris Biopharma sees 1Q revenue jump on strength of product sales
Xeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter, with total product revenue surging 25% compared to the previous year's quarter. Paul Edick, CEO of Xeris, cited significant momentum in Recorlev sales, the steadfastness of Keveyis in the market, and the expanding market share of Gvoke as key drivers of the firm's performance over the quarter.
05/09 09:10 EST - zacks.com
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.
05/06 10:01 EST - proactiveinvestors.com
Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes
Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing diabetes management. The partnership seeks to leverage Xeris' novel XeriSol technology for the development and commercialization of a glucagon product to be integrated into Beta Bionics' proprietary bi-hormonal pump and pump systems.
Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes
Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing diabetes management. The partnership seeks to leverage Xeris' novel XeriSol technology for the development and commercialization of a glucagon product to be integrated into Beta Bionics' proprietary bi-hormonal pump and pump systems.
05/06 07:00 EST - businesswire.com
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol™ technology for use in Beta Bionics' proprietary.
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol™ technology for use in Beta Bionics' proprietary.
05/02 07:00 EST - businesswire.com
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the.
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the.
04/03 16:05 EST - businesswire.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equi.
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equi.
04/02 07:00 EST - businesswire.com
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit “Events”.
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit “Events”.
03/30 01:28 EST - seekingalpha.com
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis.
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis.
03/06 09:57 EST - proactiveinvestors.com
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing borrowing interest rates. Under this agreement, Xeris secured $200 million in capital upfront, with the option to access an additional $15.2 million to redeem its outstanding convertible senior notes due in 2025.
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing borrowing interest rates. Under this agreement, Xeris secured $200 million in capital upfront, with the option to access an additional $15.2 million to redeem its outstanding convertible senior notes due in 2025.
03/06 09:16 EST - zacks.com
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
03/06 07:02 EST - businesswire.com
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern.
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern.
03/06 07:00 EST - businesswire.com
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris $200.0 million of capital at close and the ability to draw down ano.
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris $200.0 million of capital at close and the ability to draw down ano.
03/05 10:46 EST - zacks.com
Why Xeris (XERS) Might Surprise This Earnings Season
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Xeris (XERS) Might Surprise This Earnings Season
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
02/28 07:00 EST - businesswire.com
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that d.
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that d.
02/05 07:00 EST - businesswire.com
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:00 am Eastern Time. To access the presentation, please v.
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:00 am Eastern Time. To access the presentation, please v.
01/11 09:47 EST - zacks.com
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
01/10 10:52 EST - proactiveinvestors.com
Xeris Biopharma inks exclusive worldwide license agreement with Amgen for XeriJect in thyroid eye disease
Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of teprotumumab using Xeris' XeriJect technology. The collaboration aims to address Thyroid Eye Disease (TED), a severe, progressive, and potentially vision-threatening rare autoimmune disorder.
Xeris Biopharma inks exclusive worldwide license agreement with Amgen for XeriJect in thyroid eye disease
Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of teprotumumab using Xeris' XeriJect technology. The collaboration aims to address Thyroid Eye Disease (TED), a severe, progressive, and potentially vision-threatening rare autoimmune disorder.